Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy
AssigneesLentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsDina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims28
An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising one of the amino acid sequences selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 8, SEQ ID NO:
- 10, SEQ ID NO:
- 22, and SEQ ID NO:
- 24.
-13. (canceled)
-23. (canceled)
(canceled)
(canceled)
-46. (canceled)
Dependencies are inferred from the claim text.